Department of Anesthesiology, Yale University School of Medicine, New Haven, Connecticut 06520, USA.
Anesth Analg. 2010 Feb 1;110(2):478-97. doi: 10.1213/ANE.0b013e3181c6be63.
Development of hyperglycemia after major operations is very common and is modulated by many factors. These factors include perioperative metabolic state, intraoperative management of the patient, and neuroendocrine stress response to surgery. Acute insulin resistance also develops perioperatively and contributes significantly to hyperglycemia. Hyperglycemia is associated with poor outcomes in critically ill and postsurgical patients. A majority of the investigations use the term "hyperglycemia" very loosely and use varying thresholds for initiating treatment. Initial studies demonstrated improved outcomes in critically ill, postsurgical patients who received intensive glycemic control (IGC) (target serum glucose <110 mg/dL). These results were quickly extrapolated to other clinical areas, and IGC was enthusiastically recommended in the perioperative period. However, there are few studies investigating the value of intraoperative glycemic control. Moreover, recent prospective trials have not been able to show the benefit of IGC; neither an appropriate therapeutic glycemic target nor the true efficacy of perioperative glycemic control has been fully determined. Practitioners should also appreciate technical nuances of various glucose measurement techniques. IGC increases the risk of hypoglycemia significantly, which is not inconsequential in critically ill patients. Until further specific data are accumulated, it is prudent to maintain glucose levels <180 mg/dL in the perioperative period, and glycemic control should always be accompanied by close glucose monitoring.
术后高血糖的发生非常普遍,受多种因素影响。这些因素包括围手术期代谢状态、术中患者管理以及手术引起的神经内分泌应激反应。围手术期也会发生急性胰岛素抵抗,这也是导致高血糖的重要原因。高血糖与危重症和术后患者的不良预后相关。大多数研究对“高血糖”这一术语的使用非常随意,并且对开始治疗的阈值也有不同的要求。最初的研究表明,接受强化血糖控制(IGC)(目标血清葡萄糖<110mg/dL)的危重症和术后患者的预后得到改善。这些结果很快被推广到其他临床领域,IGC 在围手术期被积极推荐。然而,关于术中血糖控制价值的研究很少。此外,最近的前瞻性试验未能显示 IGC 的益处;既没有确定合适的治疗性血糖目标,也没有确定围手术期血糖控制的真正疗效。临床医生还应该了解各种血糖测量技术的技术细节。IGC 会显著增加低血糖的风险,这在危重症患者中并非无关紧要。在获得更多具体数据之前,在围手术期将血糖水平维持在<180mg/dL 是谨慎的做法,并且血糖控制应始终伴随着密切的血糖监测。